GlassScriptPhysician profile
Haley Ellison Ward
NPI 1457837569
$3,683.12
in general payments reported to CMS, 2019-2025
30 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $447 · 2023: $810 · 2024: $1,004 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Consulting Fee: $72.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.50 |
| Consulting Fee | $72.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $733.62 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $433.81 | 2023-2025 | |
| Glaxosmithkline, LLC. | $397.30 | 2022-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $223.10 | 2022-2025 | Takhzyro, Eohilia, Cuvitru |
| Csl Behring | $216.09 | 2022-2025 | Hizentra, Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $208.18 | 2022-2025 | Dupixent |
| Blueprint Medicines Corporation | $199.46 | 2023-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $140.02 | 2022-2025 | Orladeyo |
| Amgen INC. | $129.69 | 2023-2025 | Tezspire, Actimmune |
| Genentech USA, INC. | $125.35 | 2024-2025 | Xolair |
| Pharming Healthcare, INC. | $108.13 | 2022-2024 | Ruconest |
| Tersera Therapeutics LLC | $105.56 | 2025 | Quzyttir |
| Novartis Pharmaceuticals Corporation | $101.39 | 2021-2025 | |
| Adma Biomanufacturing LLC | $72.77 | 2024-2025 | |
| Pfizer INC. | $60.55 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $43.99 | 2021 | |
| Kaleo, INC. | $41.82 | 2023 | Auvi-Q |
| Boston Scientific Corporation | $39.05 | 2021 | |
| Scilex Pharmaceuticals INC. | $34.64 | 2022 | |
| Nalu Medical, INC. | $34.23 | 2022 | |
| Electronic Waveform Lab, INC. | $28.82 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $27.70 | 2025 | Neffy |
| Incyte Corporation | $26.56 | 2024 | Opzelura |
| Grifols USA, LLC | $23.82 | 2024 | Gamunex-C |
| Alk-Abello, INC | $23.75 | 2023 | Grastek, Ragwitek, Odactra |
| Spinal Simplicity, LLC | $22.36 | 2022 | |
| Cycle Pharmaceuticals INC | $21.73 | 2025 | Sajazir |
| Octapharma USA, INC. | $21.64 | 2024 | Octagam Immune Globulin (Human) |
| Forte Bio-Pharma LLC | $19.10 | 2021 | |
| Horizon Therapeutics Plc | $18.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.